Oncopeptides AB (publ) (STO:ONCO)
Sweden · Delayed Price · Currency is SEK 1.603
+0.015 (0.94%)
Jul 24, 2026, 5:29 PM CET
Oncopeptides AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 83.24 | 71.12 | 31.65 | 35.22 | 8.36 | 118.3 |
Revenue Growth | 108.91% | 124.72% | -10.14% | 321.54% | -92.94% | - |
Gross Profit Gross Profit Growth | 80.38 | 68.67 | 28.99 | 36.3 | 8.35 | 65.17 |
Operating Income Operating Income Growth | -203.34 | -225.64 | -282.59 | -252.79 | -346.94 | -1,492 |
Net Income Net Income Growth | -221.1 | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 |
Earnings Per Share EPS Growth | -0.91 | -1.10 | -1.71 | -2.76 | -4.11 | -19.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Other Countries Other Countries Growth | 0.35 | - | - |
Italy Italy Growth | 17.06 | - | - |
Germany Germany Growth | 30.82 | 17.21 | 6.57 |
Greece Greece Growth | 8.56 | 5.99 | 4.32 |
Austria Austria Growth | 1.57 | 1.13 | - |
Spain Spain Growth | 12.75 | 6.19 | - |
Asia Asia Growth | - | 1.13 | - |
Total Total Growth | 71.12 | 31.65 | 35.22 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 205.15 | 82.26 | 178.54 | 173.44 | 344.86 | 364.3 |
Total Debt Total Debt Growth | 138.8 | 139.39 | 141.72 | 131.29 | 6 | 14.19 |
Net Cash (Debt) Net Cash Growth | 66.35 | -57.13 | 36.82 | 42.15 | 338.86 | 350.11 |
Net Cash Growth | - | - | -12.65% | -87.56% | -3.21% | -57.98% |
Net Cash Per Share Net Cash Per Share Growth | 0.27 | -0.25 | 0.22 | 0.47 | 4.12 | 4.65 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -200.16 | -222.88 | -260.57 | -279.49 | -420.51 | -1,516 |
Capital Expenditures CapEx Growth | - | - | -0.36 | -0.12 | -2.51 | -0.34 |
Free Cash Flow Free Cash Flow Growth | -200.16 | -222.88 | -260.93 | -279.61 | -423.02 | -1,517 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 96.57% | 96.55% | 91.59% | 103.06% | 99.93% | 55.09% |
Operating Margin | -244.29% | -317.27% | -892.91% | -717.74% | -4152.44% | -1261.64% |
Pretax Margin | -263.84% | -348.96% | -898.03% | -705.41% | -4041.65% | -1201.55% |
Profit Margin | -265.64% | -350.94% | -899.29% | -707.30% | -4044.90% | -1209.11% |
FCF Margin | -240.47% | -313.40% | -824.47% | -793.89% | -5063.03% | -1282.16% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 7.61 | 18.43 | 10.58 | 20.58 | 137.15 | 5.35 |